-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330

Benzinga·11/13/2026 16:24:03
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $326 to $330.